← Eichor
Study identifier: NCT06517199 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Olanzapine for Cancer Related Anorexia-cachexia Syndrome

Condition: Anorexia · Cachexia  ·  Sponsor: Mahidol University

PhasePhase 3
Planned participants138
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.

This description comes directly from the study's public registry record.

Talk to the study team

Suthinee Ithimakin, MD  ·  +66824194489  ·  aesi105@yahoo.co.th

Always discuss trial participation with your own doctor first.

Locations (2)

Faculty of Medicine Siriraj HospitalBangkok, ThailandRecruiting
Division of medical oncology, department of medicine Siriraj HospitalBangkok, ThailandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06517199